WANT A PROFILE LIKE THIS?
Create my FREE Plan Or learn about other options
John Gordon
135 Points

Contributions by role

Editor 135

Contributions by subject area

Cell Biology
Molecular Biology
Hematology
Immunology
Oncology
Pharmacology

John Gordon


Summary

Co-founder and CSO of Celentyx Ltd.
Professor Emeritus of Cellular Immunology and Head of College of Medical and Dental Sciences Graduate School, University of Birmingham.
Raine Visiting Professor, University of Western Australia.

John Gordon is an internationally recognised authority on immune cell biology and immune cell-mediated diseases. For the past decade or so, John has been pioneering the field of Neuro-Immuno-Pharmacology. He is one of the world’s most highly cited researchers (www.ISIHighlyCited.com) and has a proven track record in the successful application of research within the field of translational medicine.

Cell Biology Hematology Immunology Pharmacology Translational Medicine

Editing Journals

Past or current institution affiliations

University of Birmingham

Work details

CSO, Director, co-Founder

Celentyx Ltd
http://celentyx.com/people.html
Celentyx offers bespoke Human Immuno-Profiling opportunities to partners in strategic alliance with leading international expertise in immune cell subtypes and associated pathologies within the MRC Centre for Immune Regulation at Birmingham, U.K. to mine Mechanisms of Action and disclose novel applications for new and reprofiled drugs/compounds. Predictive immuno-toxicology (unwanted reactions) can also be profiled. Specialities (compound versus human cell subsets) include assay, enumeration, and function of: Tregs; TH17; TH1/TH2; NK & NKT; Bregs; naive versus memory B cells; B1 cells; monocytes/macrophages; DCs; haematological malignancies. More recently, Celentyx has developed a suite of sophisticated platforms for evaluating novel and established biologics in the burgeoning ImmunoOncology space.

Professor Emeritus of Cellular Immunology

University of Birmingham
School of Immunity & Infection
As well as being an international force in his chosen research field of Human B-cell Biology & Pathophysiology, John has been a senior figure in the administration of the College of Medical & Dental Sciences at Birmingham holding a number of posts including that of Head of Graduate School and Associate Director of Research & Knowledge Transfer. He retired and earned Professor Emeritus status in July 2013.

Websites

  • LinkedIn
  • ResearchGate
  • Celentyx

PeerJ Contributions

  • Edited 1

Academic Editor on

February 12, 2013
Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
George W. Small, Howard L. McLeod, Kristy L. Richards
https://doi.org/10.7717/peerj.31 PubMed 23638367